NasdaqGS:HALOBiotechs
Halozyme Acquisitions And Partnerships Sharpen Drug Delivery Growth Story
Halozyme Therapeutics (NasdaqGS:HALO) has acquired Surf Bio and Elektrofi to expand its drug delivery technology portfolio.
The company has also broadened commercial partnerships and licensing agreements tied to its delivery platforms.
These moves are intended to widen Halozyme's revenue base and extend the durability of its business model over time.
Halozyme trades at $72.83, with the share price supported by a 30.4% return over the past year and a 52.8% return over five years. The stock...